Novo Nordisk Raises FY26 Adj. Sales Growth Outlook To -2% To +2% At CER From -6% To 0%
Share
Why It Matters
Novo Nordisk said its sales will shrink less than it thought before. Watch whether the company can keep fixing its problems over time.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.